1. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates

   • Shana Jacobs
   • Cynthia L. McCully
   • Elizabeth Fox

   Original Article 07 August 2009 Pages: 817 - 824

   

2. Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases

   • Hidekazu Kuramochi
   • Kazuhiko Hayashi
   • Peter V. Danenberg

   Original Article 22 August 2009 Pages: 825 - 831

   

3. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

   • Yelena Y. Janjigian
   • Wooin Lee
   • Naiyer A. Rizvi

   Original Article 12 August 2009 Pages: 833 - 838

   

4. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

   • Emma K. Hansson
   • Johan E. Wallin
   • Lena E. Friberg

   Original Article 14 August 2009 Pages: 839 - 848

   

5. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials

   • Lidan Liu
   • Yunfei Cao
   • Feng Gao

   Original Article 13 August 2009 Pages: 849 - 861

   

6. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies

   • Tanios Bekaii-Saab
   • Marisa Hill
   • Miguel Villalona-Calero

   Original Article 06 August 2009 Pages: 863 - 869

7. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer

   • Andrea Rocca
   • Roberta Maltoni
   • Dino Amadori

   Original Article 20 August 2009 Pages: 871 - 876

8. Induction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol

   • S. J. Greay
   • D. J. Ireland
   • C. F. Carson

   Original Article 13 August 2009 Pages: 877 - 888

   

9. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

   • Takashi Shida
   • Takashi Kishimoto
   • Masaru Miyazaki

   Original Article 06 August 2009 Pages: 889 - 893

   

10. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo

    • Ji-Hui Du
    • Hou-De Zhang
    • Kun-Mei Ji

    Original Article Open access 19 August 2009 Pages: 895 - 902

    

11. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line

    • Karnati R. Roy
    • Gorla V. Reddy
    • Pallu Reddanna

    Original Article 15 August 2009 Pages: 903 - 911

    

12. Optimization of the non-invasive ¹³C-sucrose breath test in a rat model of methotrexate-induced mucositis

    • K. L. Tooley
    • G. S. Howarth
    • R. N. Butler

    Original Article 19 August 2009 Pages: 913 - 921

    

13. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane

    • Zhongling Feng
    • Gang Zhao
    • Stephen B. Howell

    Original Article Open access 15 August 2009 Pages: 923 - 930

    

14. Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model

    • Nohemí Salinas-Jazmín
    • Marisol de la Fuente
    • Marco A. Velasco-Velázquez

    Original Article 19 August 2009 Pages: 931 - 940

    

15. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

    • Frederick H. Hausheer
    • Dakshine Shanmugarajah
    • Aulma R. Parker

    Original Article 28 August 2009 Pages: 941 - 951

    

16. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats

    • Yukiko Maeda
    • Akinobu Hamada
    • Hideyuki Saito

    Original Article 21 August 2009 Pages: 953 - 959

    

17. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

    • Akira Sawaki
    • Yasuhide Yamada
    • Toshirou Nishida

    Original Article Open access 19 August 2009 Pages: 961 - 967

    

18. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

    • Rhys D. Clyburn
    • Penny Reid
    • Ingunn Holen

    Original Article 03 September 2009 Pages: 969 - 978

    

19. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

    • Peter M. Wilson
    • Anthony El-Khoueiry
    • Heinz-Josef Lenz

    Clinical Trial Report 09 January 2010 Pages: 979 - 988

    

20. DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells

    • Helotonio Carvalho
    • Leandro M. Garrido
    • Carlos Frederico Martins Menck

    Short Communication 28 January 2010 Pages: 989 - 994

    

21. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine

    • Yong Chen
    • Lisa Liu
    • Sekhar Surapaneni

    Short Communication Open access 30 January 2010 Pages: 995 - 1000

22. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab

    • Brett L. Gourley
    • Hector Mesa
    • Pankaj Gupta

    Short Communication 30 January 2010 Pages: 1001 - 1004